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Abstract
Purpose Among Australian women, breast cancer is the most commonly diagnosed cancer. The out-of-pocket cost to the patient
is substantial. This study estimates the total patient co-payments for Medicare Benefits Schedule (MBS) and Pharmaceutical
Benefits Scheme (PBS) for women diagnosed with breast cancer and determined the distribution of these costs by Indigenous
status, remoteness, and socioeconomic status.
Methods Data on women diagnosed with breast cancer in Queensland between 01 July 2011 and 30 June 2012 were obtained
from the Queensland Cancer Registry and linked with hospital and Emergency Department Admissions, and MBS and PBS
records for the 3 years post-diagnosis. The data were then weighted to be representative of the Australian population. The co-
payment charged for MBS services and PBS prescriptions was summed. We modelled the mean co-payment per patient during
each 6-month time period for MBS services and PBS prescriptions.
Results A total of 3079 women were diagnosed with breast cancer in Queensland during the 12-month study period, representing
15,335 Australian women after weighting. In the first 3 years post-diagnosis, the median co-payment for MBS services was AU$
748 (IQR, AU$87–2121; maximum AU$32,249), and for PBS prescriptions was AU$ 835 (IQR, AU$480–1289; maximum
AU$5390). There were significant differences in the co-payments for MBS services and PBS prescriptions by Indigenous status
and socioeconomic disadvantage, but none for remoteness.
Conclusions Women incur high patient co-payments in the first 3 years post-diagnosis. These costs vary greatly by patient.
Potential costs should be discussed with women throughout their treatment, to allow women greater choice in the most appro-
priate care for their situation.
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Introduction
In 2018, it was anticipated that an estimated 18,087 women
would be diagnosed with breast cancer, which is the most
commonly diagnosed cancer in women within Australia [1].
Most recent estimates suggest that 5-year survival for women
diagnosed with breast cancer in Australia is 90% [1].
However, improvements in treatment and survival come at a
cost to both the healthcare system and the patient. Recent
Australian studies have highlighted that women diagnosed
with breast cancer will face significant out-of-pocket (OOP)
costs [2–4]. These high OOP costs may result in people diag-
nosed with cancer delaying or forgoing healthcare [5–7]. This
financial burden placed on individuals and their families due
to a cancer diagnosis is known as ‘financial toxicity’ [8].
Australia has a universal healthcare system, Medicare,
which has three parts: hospital, medical, and prescription
pharmaceutical. Individuals receive free treatment at public
hospitals and free or subsidized medical services outside of
public hospitals. The Medicare Benefits Schedule (MBS) in-
cludes medical services such as attendances by medical doc-
tors, tests and scans, most procedures performed by doctors,
optometrists, and some allied health services. For items listed
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on the MBS, Medicare pays a rebate (proportion of the fee) to
the service provider. If the fee charged is equal to the rebate,
the patient incurs no co-payment (the service is ‘bulk-billed’);
however, if the fee charged by the service provider is greater
than the rebate, the patient will be charged an OOP co-
payment [9]. Medical service providers in Australia may set
their own fees, resulting in unregulated OOP fees for patient
[10].
The Pharmaceutical Benefits Scheme (PBS) is a list of
approved prescription pharmaceuticals, for which the patient
is charged a co-payment, and the Australian Government
funds the remainder of the fee [9]. There are also a number
of policies in place to protect individuals and family groups
from spending a high amount on patient co-payments during
the year. Individuals and families with a concession card or
health care card may be eligible to obtain medications and
health services at a lower cost. In addition to this, the respec-
tive Medicare and PBS Safety Nets have a number of thresh-
olds which depend on the individual or family group circum-
stances, such as concessional cardholders. Once an individual
or family group reach the threshold, they will have a higher
proportion of their service/prescription subsidized for the re-
mainder of the year [9]. In 2010, the Closing the Gap (CTG)
PBS prescriptions were introduced, which allowed
Indigenous Australians to have access to PBS medicines at a
lower cost or for free [11].
There is growing concern regarding the high OOP expen-
diture associated with a breast cancer diagnosis. A recent re-
port commissioned by the Breast Cancer Network Australia
indicated that the median OOP for women was $4809 in the
first 5 years post-diagnosis (interquartile range (IQR), $1510
and $17,200) [4]. Although similar OOP costs for women
living in urban and non-urban areas were reported, women
living in non-urban areas were found to access fewer services.
Women living in non-urban areas were also reported to spend
more on accommodation costs compared with women from
urban areas [4]. In a recent Queensland study using adminis-
trative data to estimate the OOP costs of major cancers, the
median co-payment for women diagnosed with breast cancer
was $4192 (IQR, 1165–7459) during the first 2 years follow-
ing diagnosis [3]. However, the sample was relatively small
(84 women diagnosed with breast cancer), and the study did
not compare costs by sub-populations such as Indigenous sta-
tus, remoteness, or socioeconomic status. A longitudinal study
of 287 Queensland women diagnosed with breast cancer
found that the greatest total costs (direct and indirect) were
during the first 6 months post-diagnosis, followed by a grad-
ual decline over the next 18 months [2]. Costs were higher for
women diagnosed with positive lymph nodes and for younger
women (≤ 50 years) [2]. In a study of people diagnosed with
cancer and being treated at The Townsville Hospital
(Queensland), travel expenses accounted for the greatest
OOP costs (71%), followed by medical services (10%) and
medications (9%) [12]. Costs were highest for people living
further away from the hospital and for people receiving radio-
therapy [12]. The two latter studies relied on self-reported
costs, which have some limitations associated with recall.
The use of linked administrative data may overcome this
shortcoming.
A linked administrative data model (CancerCostMod) was
used in the present study to estimate the patient co-payments
for women diagnosed with breast cancer. For this study, we
adopted an individual perspective to (1) estimate the total
patient co-payments for MBS services and PBS prescriptions
for women diagnosed with breast cancer during the first
3 years following diagnosis and (2) determine the distribution
of these co-payment costs by Indigenous status, remoteness,
and socioeconomic status.
Methods
Study population
The methodology for ‘CancerCostMod’ has been previously
described [13]. Briefly, this dataset comprises all cancer diag-
noses (excluding non-melanoma skin cancer) in the
Queensland Cancer Registry (QCR) between 01 July 2011
and 30 June 2012 (N = 25,553 patients), which were then
linked with data on hospital admissions (Queensland Health
Admitted Patient Data Collection (QHAPDC)) ED presenta-
tions (Emergency Department Information Systems (EDIS)),
MBS, and PBS from 01 July 2011 and 30 June 2015. The
Queensland Health Statistical Services Branch completed the
linkage of QCR, QHAPDC, and EDIS, and then the
Australian Institute of Health andWelfare (AIHW) linked this
dataset to MBS and PBS. The base population was weighted
by the authors to the Australian population to be representa-
tive of the Australian population. The authors used a pro-
grammed SAS macro, GREGWT (weighted N = 123,900)
[13]. The 2012 Australian Cancer Database was used as the
benchmark for the weighting [14]. For this study, we extracted
from ‘CancerCostMod’ records of female breast cancer (ICD-
O C50) in those aged 18 years or greater at the time of
diagnosis.
Sociodemographic characteristics
Sociodemographic variables obtained in the QCR dataset at
the time of diagnosis were age, sex, Indigenous status, and
residential postcode. Postcode was mapped to the Index of
Relative Socio-Economic Disadvantage (IRSD) and collapsed
into quintiles (Q1 =most disadvantaged, and Q5 = least disad-
vantaged). The IRSD is a summary of the economic and social
conditions of an area and is a measure of relative socioeco-
nomic disadvantage [15]. Postcode was also mapped to the
Support Care Cancer (2020) 28:2217–22272218
Australian Statistical Geography Standard [16] to obtain a
measure of remoteness: metropolitan, regional (inner and out-
er), and remote (remote and very remote). The original QCR
dataset had 151 records with missing postcodes were unable
to be mapped to IRSD or remoteness. Indigenous status was
recorded for 87% of the sample obtained from the QCR. The
authors imputed records with missing Indigenous status.
Briefly, records of patients with missing Indigenous status
who lived in a local government area where ≥ 75% of the
population were Indigenous Australian were assigned to be
‘Indigenous.’ We then used multiple imputation to impute
the remaining records with missing Indigenous status. These
methods have been described in more detail previously [13].
Breast cancer staging
The stage at diagnosis is not routinely collected by jurisdic-
tional cancer registries in Australia. As such, we categorized
stages into ‘early’ (tumour size ≤ 20 mm with no evidence of
lymph node involvement), ‘advanced’ (tumour size > 20 mm,
or if any lymph node involvement regardless of size, or if there
was metastatic disease), and ‘unknown’ (tumour size or lymph
node involvement was unknown) using similar methods pub-
lished in previous Queensland studies [17, 18].
Assigning patient co-payments to MBS services
and PBS prescriptions
The MBS and PBS datasets used in developing
CancerCostMod included information on the date of service/
prescription, patient postcode, provider postcode, item code,
full charge, Government rebate, and patient co-payment. The
patient co-payment was summed monthly for MBS services
and PBS prescriptions from the date of diagnosis (time = 0)
for 36 months following diagnosis. If an individual died dur-
ing the first 3 years following diagnosis, no costs were record-
ed for subsequent months following death. All co-payments
were adjusted to the 2016–2017 financial year using the
Reserve Bank of Australia inflation calculator [19]. All costs
are reported in Australian dollars (AUD).
The MBS and PBS datasets include all MBS services and
PBS prescriptions, which includes oncology and non-
oncology medical services and prescriptions. This study ex-
cluded any costs associated with treatment that was not cov-
ered by Medicare, such as some medical services, over-the-
counter, or private prescriptions. Other OOP costs such as
private health insurance, hospital excess or charges, travel,
accommodation, food, or indirect costs due to changes in la-
bour force participation for the patient (and their caregiver/s)
were also excluded. Patient comorbidities were also excluded
from the dataset and, therefore, not adjusted for in the analysis.
Statistical analysis
Descriptive analyses were conducted to determine the charac-
teristics of women diagnosed with breast cancer. To describe
the total co-payment costs for this sample, we aggregated the
co-payments for MBS and PBS separately into 6-month time
periods from the date of diagnosis (t = 0) to 36 months post-
diagnosis. We report the total and average patient co-payment
separately for MBS services and PBS prescriptions during
each of the time periods analysed (limited to those who
accessed at least one health event).
Finally, we modelled the mean patient co-payment during
each 6-month time period using generalized linear models,
using a negative binomial regression, and a log link function.
There were six separate models (one for each 6-month period)
for MBS co-payments and 6 separate models for PBS co-pay-
ments. Covariates included in these analyses were Indigenous
status (reference = non-Indigenous women), age group (refer-
ence = 18–44 years), remoteness (reference = metropolitan),
socioeconomic disadvantage (reference = IRSD Q5 (least dis-
advantaged)), breast cancer stage (reference = early), number
of medical services accessed during the period analysed, and
death during the time period being modelled. These are vari-
ables that may have influenced treatment and therefore costs
associated with treatment. The models also included the num-
ber of months the individual survived as an offset to the mod-
el. All analyses were undertaken using SAS V9.4 (SAS
Institute Inc., Cary, NC, USA).
Human Research Ethics approval was obtained from the
Townsville Hospital and Health Service Human Research
Ethics Committee (HREC) (HREC/16/QTHS/11), AIHW
HREC (EO2017/1/343), and James Cook University HREC
(H6678). Permission to waive consent was approved from
Queensland Health under the Public Health Act 2005. No
identifiable information was provided to the authors.
Results
Between 1 July 2011 and 30 June 2012, 3079 women were
diagnosed with breast cancer in Queensland. This represents
15,335 Australian women once weighted. Demographic char-
acteristics at diagnosis are shown in Table 1. The mean age for
this cohort was 61 years (SD, 14 years). Demographic char-
acteristics were similar for the weighted and unweighted
sample.
During the first 12 months following diagnosis, 646 wom-
en passed away. Of this, 44% lived in metropolitan areas, 36%
lived in regional areas, and 11% lived in remote areas (please
note that due to missing postcode data, this does not add to
100%). Of those who passed away during the first 12 months
following diagnosis, 7% lived in the most disadvantaged areas
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(IRSD Q1), 3% lived in Q2, 16% lived in Q3, 46% lived in
Q4, and 20% lived in Q5 (least disadvantaged). Table 2
describes the stages of disease at diagnosis for Australian
women diagnosed with breast cancer by Indigenous status,
remoteness, and socioeconomic status.
Table 3 describes the number of MBS services and PBS
prescriptions accessed by women diagnosed with breast can-
cer during the first 3 years post-diagnosis. On average, each
woman accessed 233 services MBS services (SD, 144) during
the first 3 years following a breast cancer diagnosis and an
average of 99 PBS prescriptions (SD, 90).
A summary of the patient co-payments for MBS services
and PBS prescriptions over the first 3 years following diagno-
sis is reported in Table 4. During the first 3 years post-diag-
nosis, the average co-payments for MBS services was
AU$1440 (SD, $1946). For MBS patient co-payments, the
standard deviation was larger than the mean in each of the 6-
month periods, indicating a wide dispersion in the average
patient co-payment between individuals. This was not ob-
served for PBS prescriptions. During the first 3 years post-
diagnosis, the average co-payments for PBS prescriptions
was AU$974 (SD, $707).
The average patient co-payments for MBS services and
PBS prescriptions are shown in Fig. 1 by age group (panels
a and b), stage of disease (panels c and d), Indigenous status
(panels e and f), remoteness (panels g and h), and socioeco-
nomic disadvantage (panels i and j). In most of the panels, the
first 6 months following diagnosis accounted for a higher
proportion of patient co-payments. There is some variation
in the average co-payment for MBS services during the 0–6
and 7–12 months post-diagnosis by age group and stage of
disease, but after 12 months, there is little to no variation.
There is some variation in the average co-payment for PBS
prescriptions over the first 6 months by age group and stage
of disease. Indigenous women have lower average patient
co-payments for both MBS services and PBS prescriptions
across all time periods. There was some variation observed
in the average patient co-payment for MBS services when
Table 1 Demographic characteristics at diagnosis of Australian women
diagnosed with breast cancer between 1 July 2011 and 30 June 2012
(weighted)
N
N 3079
N (weighted) 15,335
Age group
18–44 years (%) 1848 (12.1)
45–64 years (%) 7536 (49.1)
≥ 64 years (%) 5951 (38.8)
12-month mortality 646 (4.2)
Indigenous status
Indigenous women (%) 248 (1.6)
Non-Indigenous women (%) 15,087 (98.4)
Remoteness*
Metropolitan (%) 7712 (50.6)
Regional (%) 6359 (41.7)
Remote (%) 1180 (7.7)
Index of Relative Socio-Economic Disadvantage*
Quintile 1 (most disadvantaged) (%) 1095 (7.2)
Quintile 2 (%) 767 (5.0)
Quintile 3 (%) 2483 (16.3)
Quintile 4 (%) 6669 (43.7)
Quintile 5 (least disadvantaged) (%) 4236 (27.8)
Breast cancer stage
Early (%) 6695 (43.6)
Advanced (%) 7174 (46.8)
Unknown (%) 1466 (9.6)
*Those with missing postcode data at diagnosis were excluded (weighted
n = 85)
Table 2 Stages of disease at
diagnosis of Australian women
diagnosed with breast cancer
between 1 July 2011 and 30
June 2012 (weighted)
Early Advanced Unknown
Indigenous Australian (%) 75 (30) 123 (50) 50 (20)
Non-Indigenous Australian women (%) 6620 (44) 7052 (47) 1415 (9)
Remoteness**
Major city (%) 3424 (44) 3567 (46) 721 (9)
Regional (%) 2757 (43) 3066 (48) 536 (8)
Remote (%) 514 (44) 537 (46) 129 (11)
Index of Relative Socio-Economic Disadvantage**
Quintile 1 (most disadvantaged) (%) 439 (40) 557 (51) 99 (9)
Quintile 2 (%) 368 (48) 351 (46) 49 (6)
Quintile 3 (%) 1085 (44) 1188 (48) 210 (9)
Quintile 4 (%) 3018 (45) 3078 (46) 573 (9)
Quintile 5 (least disadvantaged) (%) 1786 (42) 1995 (47) 455 (11)
**Those with missing postcode data at diagnosis were excluded (weighted n = 85)
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comparing by remoteness and socioeconomic disadvantage.
Women living in metropolitan areas appear to have slightly
higher co-payments for MBS services throughout the first
3 years compared with women living in regional and remote
areas. Women living in the least disadvantaged quintiles (Q4
and Q5) had higher patient co-payments for MBS services
compared with those living in quintiles 1–3. There was very
little variation in the patient co-payment for PBS prescriptions
by remoteness or socioeconomic disadvantage.
Table 5 shows the parameter estimates produced by the six
generalized linear models, estimating the mean patient co-
payment per patient for each 6-month time period for MBS
services, adjusting for Indigenous status, remoteness, socio-
economic status, age group at diagnosis, stage of disease at
diagnosis, number of MBS services during period analysed,
and death during time period being analysed. For MBS ser-
vices, co-payments were 82% lower in Indigenous women
during 0–6 months and 79% lower during the 7–12 months
post-diagnosis compared with those in non-Indigenous wom-
en. There were no consistent differences between areas of
remoteness. Compared with women living in the least disad-
vantaged area (Q5), women living in Q1, Q2, and Q3 had
significantly lower costs for 0–6 months and 7–12 months.
Finally, we examined the mean co-payment per patient for
each 6-month time period for PBS services, adjusting for
indigenous status, remoteness, socioeconomic status, age
group at diagnosis, stage of disease at diagnosis, number of
PBS services during the period analysed, and death during
the time period being analysed (Table 6). Co-payments were
significantly lower for Indigenous women during each of the 6-
month periods analysed compared with those for non-
Indigenous women (ranging from 41% less during months 7–
12, to 30% less during 19–24 months). There were no signif-
icant differences by remoteness in any of the 6-month periods
analysed. Compared with women living in the least disadvan-
taged quintile (Q5), patient co-payments reduced with increas-
ing disadvantage in the first 6 months post-diagnosis (Q1, 21%
fewer; Q4, 13% fewer). Women from the most disadvantaged
quintile also had 18% fewer costs during 13–18 months, 15%
fewer costs during 19–24 months, 19% fewer costs during 25–
30 months, and 16% fewer costs during 31–36 months.
Discussion
The total patient co-payments for the first 3 years for women
diagnosed with breast cancer was approximately $21.7 mil-
lion for MBS services and $14.2 million for PBS prescrip-
tions. The average patient co-payment for MBS services dur-
ing the first 3 years was $1440, with some women paying a
maximum of $32,249. In addition, the average co-payments
paid per patient for PBS prescriptions during the first 3 years
post-diagnosis was $974, with a maximum of $5390.
We presented the costs for patient co-payments for MBS
services and PBS prescriptions. A recent Queensland study
estimated the median patient co-payments for all services and
prescriptions billed through Medicare during the first 2 years
post-diagnosis was $4192 [3]. These results are also compara-
ble to other reports of high OOP costs in Australia following
a breast cancer diagnosis [2, 4]. Both of these other studies
include direct and indirect costs following a breast cancer
diagnosis. Our data set did not include costs which did not
incur a rebate paid by Medicare. However, our study is unique
Table 3 Number of MBS services and PBS prescriptions for women
diagnosed with breast cancer in Australia (weighted)
Time since diagnosis
(months)
MBS services PBS prescriptions
Mean ± SD Mean ± SD
0–6 75 ± 45 25 ± 19
7–12 47 ± 39 18 ± 17
13–18 30 ± 27 17 ± 17
19–24 28 ± 31 17 ± 17
25–30 28 ± 34 17 ± 17
31–36 26 ± 31 17 ± 17
Table 4 Patient co-payments of MBS services and PBS prescriptions for women diagnosed with breast cancer in Australia (weighted)
Time since diagnosis
(months)
MBS services PBS prescriptions
Mean ± SD
(AU$)
Median
(AU$)
Interquartile
range (AU$)
Maximum
(AU$)
Mean ± SD
(AU$)
Median
(AU$)
Interquartile
range (AU$)
Maximum
(AU$)
0–6 649 ± 845 229 1–1121 6620 326 ± 322 205 105–451 2137
7–12 294 ± 605 61 0–253 9404 175 ± 148 141 77–222 1759
13–18 145 ± 314 54 0–164 5901 156 ± 131 121 72–216 1282
19–24 140 ± 390 49 0–149 10,193 153 ± 127 115 73–219 1192
25–30 140 ± 423 54 0–145 9899 145 ± 124 112 61–193 1536
31–36 133 ± 407 44 0–138 10,745 143 ± 118 116 61–192 1203
TOTAL 1440 ± 1946 748 87–2121 32,249 974 ± 707 835 480–1289 5390
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in that it describes the distribution of patient co-payments by
Indigenous status, remoteness, and socioeconomic status.
We found that Indigenous women and women living in
areas of socioeconomic disadvantage had significantly lower
patient co-payments for MBS services during the 12 months
following diagnosis, even after adjusting for the number of
services used during this time. These findings may indicate
that the policies in place to protect individuals and family
groups from spending a high amount on patient co-payments
during the year are working. These policies include lower
payments for eligible Concession Card holders, as well as
the Medicare and Extended Medicare Safety Nets. Once an
individual or family group patient reaches the threshold set for
that calendar year, then they may receive a greater proportion
of Medicare rebate for out-of-hospital services [9].
In Australia, the rebate paid by Medicare is set in the
Schedule (a listing of all Medicare services subsidized by
the Government); however, health practitioners are able to
set the fee charged for the service provided, resulting in un-
regulated patient co-payments. Some MBS service providers
may also choose to bulk-bill patients, resulting in no patient
co-payment. Some un-referred services may be eligible for
bulk-bill incentives from the government [20]. In 2015,
OOP expenditure in Australia was 20%, which was equal to
the Organisation for Economic Cooperation and Development
average (20%), but higher than the average paid in the UK
(15%), New Zealand (13%), and Canada (15%) [21]. This is
of concern, as it is known that people may delay or forgo
healthcare due to costs [5, 7]. Previous work by some of the
authors found that 21% of Australian adults with cancer
skipped care due to the costs [5]. In a survey of people with
cancer, 10.9% indicated that the cost of treatment influenced
their decision about cancer treatment [7]. A recent study using
CancerCostMod identified that on average, Indigenous
Australians with cancer had lower patient co-payments for
MBS services and PBS prescriptions combined compared
with non-Indigenous Australians with cancer. There were also
differences in the number and type of MBS services accessed
between Indigenous Australians and non-Indigenous
Australians [22]. Future studies should identify if there are
differences in the type and number of MBS services and
PBS prescriptions for women diagnosed with breast cancer.
In relation to PBS prescriptions, we found that after
adjusting for the number of prescriptions, patient co-
payments were significantly lower in Indigenous women
and in women living in areas of socioeconomic disadvantage
(Q1–4). Again, these findings may indicate that the prescrip-
tions dispensed under the CTG scheme for Indigenous
Australians, lower co-payments for people with eligible
Concession Cards, and the PBS Safety Net may be protecting
individuals and family groups from paying excessive patient
co-payments for their prescriptions. In contrast to unregulated
patient co-payments for MBS services, patients will pay up to
the patient co-payment for approved PBS medications (2018
general patient, $39.50; and concession card holder $6.40)
[23]. However, previous studies have found that cost is a bar-
rier in obtaining the prescription [6, 24]. In a survey of people
with cancer, 11% indicated that medications prescribed for
their cancer treatment caused financial burden. Those who
had a reduced income following their diagnosis reported
greater financial burden due to prescribed cancer medications.
Almost 12% of participants indicated that they used an alter-
native (over-the-counter, medication already at home, medi-
cines from someone else) to their prescribed cancer-related
medications [6].
Our study found no consistent difference in the patient co-
payments paid for MBS services or PBS prescriptions by re-
moteness. In comparison, previous studies have reported
higher patient OOP expenditure for people living outside of
urban areas. A recent Western Australia study reported that of
people diagnosed with one of the four most common cancers,
total OOP expenditure was higher in participants residing out-
side of the South West region, who had private health insur-
ance and were under the age of 65 years. This study included
direct and indirect costs. The categories which accounted for
the greatest proportion of expenditure were surgery, tests, ac-
commodation, and fuel [25]. These results were similar to a
Queensland study, which reported travel expenses accounting
for the greatest proportion (71%) of total costs for cancer
patients [12]. OOP costs were greatest for people living more
than 100 km from the hospital in which they received care,
compared with those who lived within 100 km from this hos-
pital [12]. Our study was unable to estimate indirect costs, as
these were not covered by Medicare.
This study has several strengths, primarily due to the use of
population-based linked administrative data. We included the
patient co-payment costs of all MBS services and PBS pre-
scriptions from date of diagnosis to 36 months post-diagnosis
for women diagnosed with breast cancer. The data was
weighted to be representative of the Australian population.
We have previously calculated that the age-standardized inci-
dence rate of women diagnosed with breast cancer for
CancerCostMod was 120.56 per 100,000, compared with
the national age-standardized incidence rate of 120.42 per
100,000 for women diagnosed with breast cancer in 2012
[13]. Administrative data also overcomes potential measure-
ment bias (poor recall, self-report, interviewer, etc.). However,
administrative data also has several weaknesses. For example,
Fig. 1 Average patient co-payments for MBS services and PBS prescrip-
tions by age group (a, b), breast cancer stage (c, d), Indigenous status
(e, f), remoteness (g, h), and socioeconomic disadvantage (i, j). Average
costs per patient were calculated for each 6-month period from diagnosis
to 3 years. The figures on the left present the unadjusted average patient
co-payments for MBS services, and on the right present the unadjusted
average patient co-payments for PBS prescriptions by characteristics of
interest
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the QCR does not routinely collect stage of disease at diagno-
sis, or breast cancer type, or socioeconomic status of individ-
uals. Therefore, we identified the stage as ‘early’, ‘advanced’,
and ‘unknown’ and used aggregated area-level data to identify
socioeconomic disadvantage and remoteness. We were unable
to estimate patient OOP costs which were not covered by
Medicare, such as some medical services, over-the-counter
medications, private prescriptions, private health insurance
(including premiums and excess), travel, accommodation,
food, or indirect costs due to changes in labour force partici-
pation for the patient (and their caregiver/s). These indirect
costs are known to account for a high proportion of the costs
to the patient [2, 12, 25]. Patient comorbidities were also ex-
cluded from the dataset and, therefore, not adjusted for in the
analysis.
The sample of women diagnosed with breast cancer that
was used in this manuscript was obtained from a larger
dataset, CancerCostMod. The original data included had in-
digenous status recorded for 87% of the records [13]. In the
development of this dataset, Indigenous status was imputed
for records with missing or unknown Indigenous status.
Missing Indigenous status is a common data limitation in
Australian health studies [26]. Previously, Australian national
cancer statistics have included data from five (of eight) juris-
dictions only, as these jurisdictions are considered to have
sufficient completeness of Indigenous status for reporting
[1]. It is possible that the national statistics underestimate the
true incidence of cancer in Indigenous Australians [27]; it is
also possible that we have overestimated the number of new
cases of cancer for Indigenous Australians.
Conclusion
This study supports previous findings of high OOP co-
payments following a breast cancer diagnosis. We also found
significant differences in the patient co-payments for women
diagnosed with breast cancer in Australia by Indigenous status
and socioeconomic disadvantage. Although it may be difficult
to predict all of the patient co-payments throughout their can-
cer journey, there is a call for greater transparency for patient
co-payments. As costs are a potential barrier to accessing
treatment, health professionals should be aware of potential
co-payments which may be incurred and discuss these with
the patient throughout their cancer journey.
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